Table 1.
HLA class I restricted epitopes (I)
| Number | Residues | Sequence | HLA | Reference |
|---|---|---|---|---|
| HBsEC-1 | 20–28 | FLLTRILTI | A*02:01, 02:05, 02:06 | [13] |
| HBsEC-2 | 88–96 | LLCLIFLLV | A2 | [9, 14] |
| HBsEC-3 | 95–104 | LVLLDYQGML | A2 | [8] |
| HBsEC-4 | 172–180 | WLSLLVPFV | A*02:01, 02:02,02:03,02:05, 02:06 | [6, 8, 9, 14, 15] |
| HBsEC-5 | 207–216 | SIVSPFIPLL | A2 | [14] |
| HBsCP-6b | 169–176 | FLGPLLVL | A2a | |
| 180–187 | ||||
| 179–188 | ||||
| HBsCP-7b | 72–79 | LLGWSPQA | A2a | |
| 61–68 | ||||
| 71–78 | ||||
| HBsCP-8b | 259–266 | LLLCLIFL | A2a | |
| 248–255 | ||||
| 258–265 | ||||
| HBsCP-9b | 333–370 | FLWEWASA | A2a | |
| 332–339 | ||||
| 322–329 | ||||
| HBsCP-10b | 129–136 | PAGGSSSG | A2a | |
| 140–147 | ||||
| 139–146 | ||||
| HBcEC-11 | 18–27 | FLPSDFFPSV | A*02:01, 02:05, 02:06 | [6, 8, 9, 14–17] |
| HBcEC-12 | 88–96 | YVNVNMGLK | A11 | [18] |
| HBcEC-13 | 107–115 | CLTFGRETV | A2 | [8] |
| HBcEC-14 | 117–125 | EYLVSFGVW | A24 | [19] |
| HBcEC-15 | 139–148 | ILSTLPETTV | A2 | [8] |
| HBcCP-16 | 141–148 | TLPETTVV | A2 | |
| HBcCP-17 | 160–168 | PSPRRRRS | A2 | |
| HBcCP-18 | 64–71 | LMTLATWV | A2 | |
| HBcCP-19 | 29–36 | LLDTASAL | A2 | |
| HBcCP-20 | 107–114 | LTFGRETV | A2 |
Name and amino acid position of the 20 epitopes. HLA genotype indicates which genotypes were tested in previous studies (HBsEC1-5 and HBcEC11-15), or which genotypes we stratified for in the in silico analysis (HBsCP6-10 and HBcCP16-20)
HBsEC HBsAg experimentally confirmed, HBsCP HBsAg computer predicted, HBcEC HBcAg experimentally confirmed, HBcCP HBcAg computer predicted
aall subtypes
bdifferences of sequence position among HBV genotypes was observed for in silico prediction of HBsAg